Wolfgang Miesbach: New Editorial Highlights – 6 Year Outcomes of Hemophilia B Gene Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article he and his colleague co-authored, published in Blood Advances, adding:
“Happy to share that our editorial is now online in Blood Advances.
We discuss the 6‑year follow‑up of a phase 1/2 study in 14 adults with severe or moderately severe haemophilia B who received a single IV infusion of fidanacogene elaparvovec (5 × 10¹¹ vg/kg), reporting durable FIX levels in the mild range at year 6, sustained bleed reduction, and clinically meaningful improvements in patient‑reported quality of life.
We also highlight safety and methodological nuances, including ALT elevations in 8/14 participants during years 2–6, hepatic steatosis in those with elevated baseline BMI, interindividual variability in FIX expression, and the implications of Pfizer’s withdrawal of Beqvez despite these encouraging long‑term outcomes.
Many thanks to my co‑author Roland W Herzog for this excellent collaboration.”
Title: Six-year FIX-padua gene therapy in hemophilia B
Authors: Wolfgang Miesbach, Roland Herzog

Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 14, 2026, 13:09Antonio Galante: Management of Portal Vein Thrombosis
-
Nov 14, 2026, 12:47Yasmin Mohtasham Kia: Anticoagulation Knowledge and Treatment Outcomes in Patients With Mechanical Heart Valves
-
Nov 14, 2026, 12:37Nathan Connell: Annualized Bleeding Rate and the Future of Hemophilia A Treatment
-
Nov 14, 2026, 12:3210 Posts Not to Miss This Week
-
Nov 14, 2026, 11:28Kalyan Roy: A New Era in Thalassemia Treatment – FDA Approves Mitapivat
-
Nov 14, 2026, 11:24Can Iron Deficiency Really be Seen in Someone’s Face? – ASH
-
Nov 14, 2026, 11:19Lindsay Davison: Putting Childhood Anemia in the Spotlight with IronUp and Danone
-
Nov 14, 2026, 10:00Benjamin Tur: Putting Iron Deficiency Anemia on the Global Agenda at the Paris Peace Forum’s Child Summit
-
Nov 14, 2026, 09:48Jack Shuang Hou: FDA Approves Bayer’s Sunharbo – First Factor XIa Inhibitor for Secondary Stroke Prevention